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The gut microbiota provides essential signals for the development and appropriate function of the immune system. Through this
critical contribution to immune fitness, the gut microbiota has a key role in health and disease. Recent advances in the
technological applications to study microbial communities and their functions have contributed to a rapid increase in
host–microbiota research. Although it still remains difficult to define a so-called ‘normal’ or ‘healthy’ microbial composition,
alterations in the gut microbiota have been shown to influence the susceptibility of the host to different diseases. Current
translational research combined with recent technological and computational advances have enabled in-depth study of the link
between microbial composition and immune function, addressing the interplay between the gut microbiota and immune
responses. As such, beneficial modulation of the gut microbiota is a promising clinical target for many prevalent diseases
including inflammatory bowel disease, metabolic abnormalities such as obesity, reduced insulin sensitivity and low-grade
inflammation, allergy and protective immunity against infections.
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INTRODUCTION
Hippocrates was quoted as saying ‘all disease begins in the gut’ and
over 2000 years later we are beginning to appreciate his sentiment.
Our body is colonised by a large number of microbes (bacteria, fungi,
archaea, viruses and protozoa); which mostly reside within the
gastrointestinal (GI) tract, are predominantly bacterial, and together
these microbes collectively form the gut microbiota. Often denoted
previously as commensal organisms, we now know the gut microbiota
acts in a symbiotic manner that is also beneficial for its host.1 Interest
in the gut microbiota, most notably the bacterial communities, has
recently exploded, and we are beginning to uncover how crucial these
microbes are to appropriate immune function and lifelong health, or
conversely, susceptibility to inflammatory and infectious diseases.
Early in life the GI tract quickly becomes colonised by microbes,
and the gut microbiota is purported to reach an adult state at around 3
years of age.2 Bacteroidetes and Firmicutes are the dominant phyla,
making up more than 90% of the total microbial population in both
mice and humans. Other major phyla present in the gut include the
Proteobacteria, Tenericutes, Actinobacteria and Verrucomicrobia.3
The gut microbiota has an important role in homoeostasis by
controlling metabolic pathways, nutrient metabolism and the produc-
tion of vitamins.4 Furthermore, it has also been shown to be essential
in the development and maturation of mucosal and systemic immune
responses, and for the maintenance of intestinal epithelial barrier
function.4 The importance of microbial signalling for immune
development in the GI tract has also been demonstrated in germ-
free (GF) mice, which have underdeveloped gut-associated lymphoid
tissues (GALT) including Peyer’s patches, isolated lymphoid follicles
and mesenteric lymph nodes.5 Taken together, host–microbiota
interactions are critical for host immunity and health.
Here, we review the recent advances in gut microbiota analysis, and
define the computational approaches that can be utilised to expand
our ever-growing understanding of the role of the gut microbiota in
health and disease. The immense interest and impact of the gut
microbiota in current research can mainly be attributed to the recent
advances in these applications to study microbial communities and
their functions. We also detail key microbial cross talk with the
immune system, resulting in critical instruction of appropriate
immunity. Finally, we have considered immune-mediated diseases
where the relationship between the gut microbiota and disease
susceptibility is currently most convincing, including inflammatory
bowel disease (IBD), obesity-related inflammatory disorders, allergic
and infectious diseases.1 Where applicable, the influence of key factors
such as diet or antibiotic use on the composition of the gut microbiota
is outlined. As well, we explore the use of GF mice, and gnotobiotic
mouse models where GF mice are colonised with defined microbial
communities, which provide a tool to elucidate the function of the gut
microbiota in a disease setting.
TECHNOLOGICAL APPLICATIONS FOR ASSESSING GUT
MICROBIOTA
Researchers now routinely use a wide-range of culture-dependent and
high-throughput culture-independent methods to assess gut microbial
communities. The recent advances of the culture-independent
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methods analysing the DNA (metagenomics), RNA (metatranscrip-
tomics), proteins (metaproteomics) and metabolites (metametabolo-
mics) present within the gut will be the focus of this section (Figure 1).
The development and reducing costs of next-generation sequencing,
also known as high-throughput sequencing, combined with improved
computational tools allowing for the analysis of large and complex
data sets, have led to an enormous growth in the research field. Each
tool provides unique information to interpret the different species that
live within the gut; to provide understanding of how these species
function; and describe why certain species may contribute to disease,
or respond differently to specific stimuli such as changes in diet.
Initial efforts to characterise the gut microbiome using next-
generation sequencing of gut microbiota involved the use of a ‘marker’
gene that serves as a unique fingerprint for different bacterial genera.
Amplicon sequencing is a PCR-based method that provides informa-
tion about the different microorganisms present within a sample. As
such, the bacterial communities within the gut can be assessed by
sequencing the variable regions of the 16S ribosomal RNA (rRNA)
encoding gene sequence found in bacteria and Archaea,6 whereas
eukaryotic organisms (fungi, parasites and the host) can be assessed by
sequencing the 18S rRNA encoding sequence.7 Today, this method
still provides an inexpensive way to compare bacterial communities
between patients, and assess alterations over time within a patient.
However, this 16S sequencing cannot be routinely used to identify
specific bacterial species as the 16S rRNA gene typically lacks sufficient
phylogenetic information to differentiate between taxa at the species
level,8 and some bacterial genera can share greater than 99.5% of their
16S rRNA sequences.9
Metagenomic (shotgun) sequencing was later utilised to provide
strain level resolution of all the species present within a microbial
community. Instead of employing an individual marker gene, a
random subset of the DNA present within the sample is sequenced,
and the bacterial, viral and eukaryotic species associated with the
sequences can then be reconstructed using high-powered bioinfor-
matic tools. This relatively expensive method is now becoming more
widespread as costs continue to decrease. It has also been employed to
provide information about the host GI tract through non-invasive
sampling, as DNA from the cells within the GI tract can be detected
within faecal samples.10 Despite being a very small proportion of the
gut microbiome, even viruses present within the metagenome can be
assessed using different sample preparation steps and metagenomic
sequencing.11,12 Using DNA hybridisation prior to sequencing, further
adaptations of metagenomic sequencing have included enrichment or
capture of DNA sequences specific to the species of interest.13 Within
a clinical setting, this approach could be adapted to identify specific
pathogens or disease-associated species from within an individual’s gut
microbiota without sequencing all of the DNA within a sample,
decreasing costs and the bioinformatic processing time for clinicians.
In addition to identifying specific strains, metagenomic sequencing
can also assess the functions that microorganisms can perform, as
genes within the microbial genomes are linked to the ability of an
organism to execute certain tasks. The functional capability of a
bacterial community can also be predicted based on its 16S rRNA
amplicon profile by comparing against databases containing fully
sequenced and annotated bacterial genomes.14 However, metagenomic
DNA sequencing remains the only way to identify functions from
unknown species or unique microbial communities. Metatranscrip-
tomic approaches, or the sequencing of RNA present within a sample,
have also been applied to assess the current or ongoing functions
of a metagenome within a specific period of time.15 Although
metagenomic sequencing will divulge the total functional capacity of
a microbial community, metatranscriptomics reports genes that are
being actively transcribed at a given time. Further use of metatran-
scriptomic approaches linked with RNA sequencing of the host will
reveal more information about how distinctive microbial functions are
linked to disease, and how they alter human health.
Lastly, metaproteomic and metametabolomic approaches have also
been developed. Metaproteomic studies examine the proteins that
typically result from the microorganism,16 but can also result from
inflammatory responses of the host.17 Moreover, shotgun proteomic
approaches have identified unique proteins present within the gut that
were not predicted by metatranscriptomic approaches,17 highlighting
the yet unknown nature of many interactions between the gut
microbiota and the host. Similarly, metametabolomic approaches also
use a shotgun-like approach to examine a broad range of metabolic
by-products and secretions of microorganisms that provide insight
into active microbial functions and interplay between microbial
species as well as the gut microbiota and the host.18 Many GI diseases
linked to the gut microbiota may be associated with altered proteins or
metabolite production, rather than a depletion of certain microbes.
Once certain proteins and metabolites can be linked to microbiota-
associated diseases, downstream applications will likely revolutionise
our ability to quickly and efficiently detect alterations in the gut
microbiota that are linked to disease phenotypes. This can provide
previously unavailable insight into the metabolic pathways of the
microbial community and how this intersects with the metabolism of
the host.
This knowledge could provide a basis for the crucial next step and
the remaining challenge for this research field, to establish causal
relationships between the gut microbiota and the host. Colonisation of
GF mice with mouse or human gut microbiota (referred to as
humanised mice) has been used to demonstrate a causal role for the
gut microbiota in immune development and disease susceptibility. It is
likely that the emerging technological applications will move beyond
the current focus of the bacterial communities present towards their
function; which holds the most promise for the identification of
microbial or metabolite based therapeutic strategies for prevention and
treatment of inflammatory and infectious diseases.
GUT MICROBIOTA AND LOCAL IMMUNE CELL CROSS-TALK
The GI tract must remain non-responsive to food antigens and the gut
microbiota, while being capable of responding quickly to invading
pathogens. One of the first defence mechanisms afforded by the gut
Figure 1 Overview of current technological applications available for the
assessment of gut microbial communities.
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microbiota is limiting the access of pathogenic bacteria to the gut
epithelium by competitive exclusion. The gut microbiota also
promotes secretory immunoglobulin (Ig)A production that binds to
microbes at mucosal surfaces, neutralises toxins and contributes to
microbial tolerance.19 Furthermore, bacterial molecular patterns are
sensed by innate pattern recognition receptors (PRR) such as Toll-like
receptors (TLR) or Nod-like receptors, which have a role in the
maintenance of intestinal epithelial cell (IEC) homeostasis. The
microbiota also contributes to the priming signal of the inflammasome
pathway, leading to the transcription of cytokines such as tumour
necrosis factor (TNF)-α and interleukin (IL)-6, as well as pro-IL-1β
and pro-IL-18.20 The inflammasome, activated by a variety of
pathogens including various viruses, can regulate the cleavage of these
inactive precursors to active IL-1β and IL-18.21
The gut microbiota also helps to maintain immune homeostasis by
stimulating different arms of the T-cell response. Segmented filamen-
tous bacteria (SFB) are potent promoters of T helper (Th)17 cells in
the intestine, which are important in protection against bacterial and
fungal infections.22 SFB adhesion to IEC results in the activation of the
IL-23 pathway, leading to IL-22 production by group 3 innate
lymphoid cells (ILC3) and a subsequent Th17 response.23 Conversely,
polysaccharide A from Bacteroides fragilis was shown to stimulate the
generation of FoxP3+ regulatory T cells (Treg) via TLR2 activation,24
and microbial-derived butyrate has also been shown to induce colonic
Treg.25
Fermentation of dietary fibre in the colon by anaerobic bacteria
generates short-chain fatty acids (SCFA) including butyrate, acetate
and propionate.26 As such, fermentable dietary fibre is often referred
to as microbiota accessible carbohydrates (MAC). SCFA signal via
G-protein coupled receptors (GPCR) such as GPR41, GPR43 and
GPR109A on epithelial cells and immune cells.26 When SCFA are
taken up by host cells they serve as an energy source for metabolism.
SCFA can also inhibit histone deacetylases that in turn affects gene
transcription.26 SCFA were also shown to inhibit the transcription
factor nuclear factor kappa B (NF-κB) leading to reduced inflamma-
tory cytokine production.27 Furthermore, SCFA have been demon-
strated to promote mucous production by intestinal goblet cells,
induce secretory IgA and activate the inflammasome resulting in IL-18
secretion.26,28 Importantly, systemic SCFA also reach other organs
such as the bone marrow and lung via the circulation.29
When MAC beneficially affect the host’s health by selectively
changing the composition or activity of the gut microbiota, they can
be referred to as prebiotics.30 Probiotics are defined as live micro-
organisms, which when administered in adequate amounts confer a
health benefit on the host.31 Probiotics can interfere with the growth
or survival of pathogens in the gut lumen, improve gut barrier
function and immunity, or have an effect on the systemic immune
system and organs.31 The molecular mechanisms by which probiotic
strains act are still largely unknown and require a strain-specific
approach as different probiotic strains can induce differential effects.
Both pre- and probiotics can be useful for the beneficial modulation of
the gut microbiota, and their capability to enhance immune function
has been studied for many years.30,31
INFLAMMATORY BOWEL DISEASE
No longer viewed as merely passengers, the gut microbiota has a
critical role in the development and progression of IBD, and is the
most extensively investigated with respect to the influence of the gut
microbiota on disease susceptibility, relapse and remission. Although
the specific microbial changes appear to vary from study to study,
some broad patterns are apparent. These include a loss of community
diversity, increased representation of some Gammaproteobacteria, and
decreased relative abundance of several taxa within the Firmicutes
phylum.32
Loss of faecal community diversity has been consistently shown in
human IBD studies.33–35 The most prominent change in diversity
associated with IBD is decreased abundance of the Firmicutes phylum,
which includes a loss of Faecalibacterium prausnitzii, a bacterium with
significant anti-inflammatory effects.33 Other species with decreased
representation in IBD include Bacteroides fragilis, B. vulgatus,
Ruminococcus albus, R. callidus, and R. bromii, which were over
5-fold more abundant in healthy subjects compared with IBD
patients.34 In addition to the loss of diversity and altered composition,
recent metagenomic studies showed that the overall quantity of
bacteria is also reduced in IBD. On average, 25% fewer microbial
genes could be detected in the faecal community of IBD patients,
pointing to lower functional as well as taxonomic diversity. Indeed,
some evidence suggests that the abundances of metabolic pathways are
more consistently altered in IBD than the actual taxonomic
abundances.32
Conversely, specific taxa that are increased in IBD patients include
Enterobacteriaceae, such as Escherichia/Shigella.32 In particular,
adherent-invasive E. coli strains have been identified within ileal
biopsies from Crohn’s disease patients,36 and are more prominent in
this environment compared with faecal samples.37 The increase in
Enterobacteriaceae in the small intestine may reflect their capacity to
use sialic acid and fucose liberated from mucous.38 Under normal
circumstances, these bacteria are likely to be outcompeted for this
resource by the resident microbial community, but the alterations in
the gut microbiota that occur with IBD may present the opportunity
for these bacteria to flourish.38 Other mucous associated bacteria
suspected of having an important role in IBD are the sulphate-
reducing bacteria such as Desulfovibrio piger.39 In the gut, sulphate-
reducing bacteria consume hydrogen to produce H2S by removing
sulphate from sulfated mucous glycans.40 Potential links between H2S
and IBD include genotoxic properties and the chemical disruption of
the mucous structure, as sulphides are potent reducers of disulphide
bonds.41
Specific groups of bacteria may also provide protection against
IBD, by ameliorating the inflammatory response. Bacteroides
thetaiotaomicron has been shown to suppress NF-κB and attenuate IEC
inflammation.42 Further evidence for beneficial effects of gut micro-
biota in immune modulation are found in mice with impaired
recognition of bacteria through deletion of TLR4 or its downstream
signalling molecule myeloid differentiation primary response gene 88
(MyD88), which experience worse symptoms of GI inflammation
when exposed to DSS compared with wild-type mice.43 In addition,
activation of the inflammasome can occur via MAC modulation of the
gut microbiota as well as SCFA administration, which promoted
IL-18-mediated epithelial repair following DSS-induced GI
inflammation.28 Butyrate produced by the gut microbiota, most likely
by members of the Clostridia class, has also been shown to induce the
expansion of Treg in mice, ameliorating intestinal inflammation in an
adoptive T-cell transfer model of colitis.25 Other bacteria, such as
F. prausnitzii, Bifidobacterium and Lactobacillus protect the host
through a variety of mechanisms, including modulation of cytokine
production33,44 and strengthening gut barrier function.45 The evidence
for the efficacy of probiotic strains like Bifidobacterium and
Lactobacillus in reducing the symptoms of Crohn’s disease in humans
remains unclear, although some beneficial effects have been shown in
patients with ulcerative colitis.46 In addition, the gut microbiota may
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protect the host by outcompeting pathogenic bacteria that drive GI
inflammation by preventing these pathogens from occupying niches.38
The incidence and prevalence of IBD is progressively rising, making
the condition a global health problem with currently no permanent
therapeutic treatment. Therefore, finding alternative strategies for
treating IBD is an area of increasing importance. One potential
therapy of interest is faecal microbiota transplantation (FMT), which
has been particularly successful in treating C. difficile infections.47
However, so far, FMT for treating IBD has been shown to have
variable efficacy,48 and long-term safety for FMT is largely unknown.
Risks include the possible transmission of infectious agents or
antibiotic resistance genes within FMT, or the possible induction of
other microbiota-associated diseases following FMT to a susceptible
host. Nonetheless, gut microbiota based treatments hold promise as a
future therapy for IBD patients.
OBESITY-RELATED INFLAMMATORY DISORDERS
The world is facing an epidemic of obesity-related metabolic
abnormalities, collectively known as metabolic syndrome. The
hallmarks of metabolic syndrome include hyperglycaemia,
hyperlipidaemia, insulin resistance, obesity and hepatic steatosis.49
Both lifestyle and genetic factors have a role in the development of
obesity, and recently the gut microbiota has been suggested to be a key
environmental factor that influences metabolic syndrome.50
The heritability of the gut microbiota has previously been examined
linking the abundance of specific gut microbial taxa to host genetics.51
Among the heritable taxa were members of the Firmicutes phylum
that are associated with leaness.51 Thus, host genetics influence the
composition of the human gut microbiota, and this can impact host
metabolism. Nonetheless, the diet has been suggested to be most
influential in shaping the composition of the gut microbiota.51,52 An
increase in the ratio of Firmicutes to Bacteroidetes, as well as a marked
reduction in the bacterial diversity of the gut microbiota, have been
associated with obesity in both genetic- and diet-induced mouse
models3,53,54 and clinical obesity.55,56 Moreover, diets that limit weight
gain led to a reduction in the relative abundance of Firmicutes and an
increase in Bacteroidetes in both mice and humans.53,55 However,
other investigations have shown no association between obesity and
the Bacteroidetes to Firmicutes ratio, or the diversity of the human gut
microbiota, suggesting the relationship between obesity and the gut
microbiota is highly complex and difficult to interpret.57
There is now a large body of evidence that supports the close link of
obesity and insulin resistance with chronic, low-grade inflammation,
and the gut microbiota has been implicated in the development of this
inflammatory response.58 Both diet and genetic factors can alter the
gut microbiota and impair intestinal integrity, leading to metabolic
endotoxemia, obesity, glucose intolerance and insulin resistance via
activation of TLR4 and subsequent inflammatory cytokine
production.58,59 Moreover, restoration of the gut microbiota by the
MAC oligofructose resulted in amelioration of the inflammation as
well as the associated metabolic abnormalities.60 Other TLR responses
have been linked to obesity-induced inflammation and insulin
resistance as well. For example, TLR5 sensing of bacterial flagellin is
required for gut microbial homeostasis. Consequently, TLR5 deficient
mice have altered gut microbiota and are prone to the development of
metabolic syndrome.49
The gut microbiota provides enzymes that increase caloric harvest
from MAC and the resulting monosaccharides are absorbed or
metabolised to SCFA. These products get delivered to the liver, where
lipogenesis results in hepatic triglyceride (TG) production. In addition,
the gut microbiota acts to enhance lipoprotein lipase-directed
deposition of these TG into adipocytes, promoting the storage of
calories harvested from the diet into fat. Fat storage is reduced in GF
compared with conventional mice, and colonisation of these GF mice
with gut microbiota results in a 60% increase in body fat within two
weeks.50 This body fat increase was accompanied by decreased insulin
sensitivity and increased liver TG.50 GF mice also have increased host
metabolism of fatty acids that protects against diet-induced obesity
provoked by a prototypic high-fat, high-sugar Western-style diet.61
Furthermore, depletion of the gut microbiota using an antibiotic
cocktail was sufficient to reduce adiposity and improve glucose
tolerance and insulin sensitivity by promoting browning of adipose
tissue in both diet and genetically induced obese mice.62
Colonisation of GF mice with the gut microbiota from mice with
either genetic or diet-induced obesity increased host fat deposition
compared with colonisation with microbiota from lean mice.53,54
Humanised mice from obese donor microbiota also showed more
weight gain and fat deposition than humanised mice with lean donor
microbiota.63 Cohousing lean with obese humanised mice prevented
the obese phenotype in these cage mates, and altered the microbiota to
a more lean-like profile.63 The transfer of faeces from standard diet-
fed compared with high-fat diet-fed donor mice was also sufficient to
reduce the expression of inflammatory cytokines and lipogenic genes
in adipose and hepatic tissue of mice with diet-induced obesity.64
These data suggest that there are available niches in the obese donor
microbiota that can be filled by lean associated microbes. FMT from
lean donors into humans with metabolic syndrome was also sufficient
in the clinical setting to increase gut microbial diversity and improve
insulin sensitivity.56 This opens the opportunity to determine specific
bacterial species for transplantation and the treatment of metabolic
abnormalities as a therapeutic approach in the future. Some preclinical
studies have reported beneficial effects of pre- and probiotics, yet the
data from human randomised controlled trials are inconsistent, and
more investigations are needed to inform clinical practice.
Epidemiologic studies imply that disruption of the gut microbiota
early in life, via caesarean section as well as antibiotic therapy,
increases the risk of being overweight later in childhood.65,66 Indeed,
antibiotic use during the first 6 months was associated with becoming
overweight later in life among children of normal weight mothers.
However, early administration of antibiotics reduced the risk of
becoming overweight among children of overweight and obese
mothers.65 Taken together with the preclinical data, this demonstrates
the complex relationship between the gut microbiota, antibiotic use
and metabolic outcomes. In light of the high rates of childhood
obesity, the use of antibiotics or pre- and probiotics to restore
intestinal homeostasis and to potentially prevent obesity in children
from overweight and obese mothers is an interesting concept.65 So far,
there is no direct clinical evidence for a causal relationship between
obesity and antibiotic use or delivery mode. Yet, preclinical studies
imply that even transient alterations in the infant gut microbiome
could potentially affect metabolic homeostasis resulting in obesity. In
mice, exposure to low dose antibiotics in early life resulted in an
increased risk of obesity.67,68 Low dose antibiotics do not deplete the
microbiota but cause a shift in taxonomic composition towards an
increased Firmicutes to Bacteroidetes ratio.67 There was a trend
towards hyperglycaemia in antibiotic treated mice and genes related
to hepatic lipogenesis were upregulated, but no phenotypic signs of
hepatic steatosis were observed.67 In a more recent study, Cox et al.68
showed that the period around birth was critical to alter host
metabolism and adiposity. The metabolic phenotype persisted after
cessation of the antibiotic treatment, even though the microbiota
recovered.68 This study provides evidence for a critical window in early
Gut microbiota in immunity
LWJ van den Elsen et al
4
Clinical & Translational Immunology
life when the gut microbiota can induce long-term alterations in host
metabolism.68
Taken together, the gut microbiota has a substantial effect on
metabolic abnormalities by influencing the efficiency of energy harvest
and storage, low-grade inflammation and browning of adipose tissue.
Notably, there are risk factors for these metabolic abnormalities
beyond gut microbes, which include lifestyle factors such as energy
intake and expenditure as well as genetic risk factors. This results in a
complex interplay of these lifestyle, microbial and host factors that
determine disease susceptibility. The integration of modern applica-
tions to assess microbiota in preclinical and clinical studies will help
clarify this complex interplay and yield promise to identify novel
treatments for beneficial modulation of the gut microbiota to improve
metabolic health.
ALLERGIC DISEASES
Allergic diseases are a global health concern, affecting over half a
billion people worldwide. Genetic and molecular risk factors are
clearly associated with the development of allergy; however, it is
unlikely genetic factors can account for the rapid rise in allergic disease
over the past 50 years. This indicates that environmental factors, such
as the gut microbiota, may have a key role in the development of
allergic disease. For example, reduced gut microbial diversity in infants
was associated with increased allergic risk in school age children,69 and
the development of food allergy was associated with altered gut
microbiota in these infants.70 Strikingly, a recent study has shown that
lower abundance of bacteria such as Bifidobacterium, Akkermansia and
Faecalibacterium, along with higher abundance of particular fungi
including Candida and Rhodotorula in neonates may predispose to
allergy susceptibility by influencing T-cell differentiation.71
GF mice have been an effective way to address several questions
regarding the relationship between the gut microbiota and allergic
inflammation. Colonisation of GF mice with gut microbiota in early
life was sufficient to protect mice from allergic inflammation in the
lung, whereas allergic airway inflammation (AAI) persisted in mice
colonised as adults.72 Early life colonisation with gut microbiota also
inhibited serum IgE responses,73 and protected against sensitisation to
food allergens.74 In addition, Clostridia-induced IL-22 has also been
shown to reduce the uptake of dietary antigen into the systemic
circulation.74 These investigations suggest that the gut microbiota is a
key environmental factor in the regulation of allergic inflammation in
the lung and GI tract. Depletion of the gut microbiota using antibiotic
administration in mice has also been employed to examine the impact
on allergy susceptibility. Vancomycin is not absorbed from the
intestine, so when administered orally affects only the gut microbiota.
Oral administration of vancomycin in early life resulted in exacerba-
tion of AAI and serum IgE,75 and exposure of neonatal mice to an oral
antibiotic cocktail also supported food allergen sensitisation.74 These
data show that antibiotic use increased the risk of allergy development
later in life.
SCFA and diets high in MAC also influence the development of
allergic diseases. Mice lacking SCFA receptors GPR4129 or GPR4376,77
developed more severe AAI than wild-type littermates, and high MAC
diet-suppressed AAI.29,77 Dietary MAC and SCFA also promoted Treg
induction, oral tolerance and protected against experimental food
allergy.78 Further studies identify the lung microbiota as key player in
suppressing AAI. In mice, the neonatal airways contained predomi-
nantly Firmicutes and Gammaproteobacteria, and these neonatal mice
were more susceptible to AAI.79 An expansion of Bacteroidetes in the
lung and the development of Treg cells with age were correlated with
reduced AAI.79 Asthmatic patients have also been shown to have
higher bacterial burden and diversity compared with controls.80 These
data may reflect an interplay between the microbiota at these mucosal
tissues. However, the function of the gut microbiota in atopic
dermatitis (AD) is less clear. Similarly, the impact of the gut
microbiota in eosinophilic GI diseases, such as eosinophilic esopha-
gitis, as well as other allergic disorders including allergic rhinitis and
allergic conjunctivitis, are yet to be fully elucidated.
Importantly, these findings in mice are supported by epidemiolo-
gical data that early life exposure to microbes can reduce the incidence
of allergic disease. Indeed, allergy is reduced in children exposed to a
farm environment, and studies suggest microbial exposures in early
life are a contributing factor.81 On the basis of these data, a large
number of clinical studies have examined the efficacy of probiotics in
the prevention and treatment of allergy. Utilising probiotics for the
prevention of AD has been extensively studied, yet there is still
conflicting data. As well, more studies are needed to determine the
potential for prebiotics in allergy prevention at present. Two notable
studies support beneficial modulation of the gut microbiota and
associated metabolites in early life as an effective intervention strategy
for allergic disease. The Canadian Healthy Infant Longitudinal
Development (CHILD) Study identified a transient alteration in the
gut microbiota during the first 100 days of life in infants at risk of
asthma, which was associated with reduced faecal acetate
concentrations.82 This disturbance of the microbial composition in
infants at risk was characterised by significantly lower abundance in
the gut of Lachnospira, Veillonella, Faecalibacterium and Rothia
bacterial genera.82 Colonisation of GF mice with these specific gut
microbiota ameliorated AAI in the offspring, demonstrating a causal
role for the bacterial communities in reducing allergy susceptibility.82
Moreover, the gut microbiota of infants with cow’s milk allergy is
altered in composition and diversity as compared with non-allergic
infants.83 Supplementation of extensively hydrolysed formula with a
Lactobacillus probiotic has been shown to accelerate tolerance to cow’s
milk in infants with cow’s milk allergy, and was associated with
increased abundance of faecal butyrate producing bacteria and
butyrate levels following Lactobacillus treatment.83
Taken together, there is mounting evidence to support gut
microbiota based treatments to reduce susceptibility to allergic disease.
Future research identifying the components of the gut microbiota that
influence allergy avoidance or tolerance mechanisms is crucial to
develop these strategies for widespread clinical use.
INFECTIOUS DISEASES
Nearly one third of deaths in low-income countries are attributable to
infectious diseases.84 Infection rates in the Western world have
reduced dramatically over the past century due to advances in hygiene,
antibiotic use and vaccination. However, infectious disease still poses
significant risk to vulnerable populations such as infants and the
elderly. Influenza and pneumonia remain one of the leading causes of
death of elderly citizens.85 Upper respiratory tract infections are the
most common illness for which people seek medical care, and the
burden on healthcare services is substantial.86 In addition, C. difficile is
the leading healthcare-acquired infection, which has increased in
severity and morbidity over the last decade.47 The gut microbiota
provide critical signals for the development and function of the
immune system that provides protection from invading intestinal
pathogens.87 Therefore, manipulation of the gut microbiota is an
attractive therapeutic target to build immune capability to combat
infectious diseases.
Interactions between epithelial cells and the gut microbiota are
essential for intestinal homeostasis and barrier defences. Defined gut
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microbial species have been shown to maintain tight junction
integrity, which in turn limits Salmonella typhimurium invasion.88
Gut microbiota promote the secretory IgA response that inactivates
rotavirus and neutralises cholera toxin,87 and outcompete C. difficile
colonisation thereby preventing infection.47 Key gut microbial species
also prime the development of cellular immune responses in the GI
tract. SFB-induced Th17 responses are sufficient to promote immunity
against the intestinal pathogen Citrobacter rodentium.89 Moreover,
damage induced by pathogens is limited by microbiota-induced Treg.
B. fragilis-induced IL-10 producing Treg limit Helicobacter hepaticus
infection, and Bifidobacterium infantis-induced Treg dampen excessive
inflammation induced in S. typhimurium infection.87
The critical role for the gut microbiota in establishing immune
defence against infection extends far beyond the local environment of
the GI tract. In fact, recent evidence demonstrates that gut microbial
signalling actively shapes the systemic immune response by controlling
haematopoiesis in primary immune sites.90 Microbiota derived signals
maintain granulocyte/monocyte progenitor development in the bone
marrow, which influenced multiple tissue-resident innate immune
populations. This in turn dictates the efficiency of early innate
Figure 2 The gut microbiota affects various inflammatory and infectious diseases. IBD is associated with reduced diversity of the microbial community and
other specific microbial changes associated with GI inflammation. A reduction in short-chain fatty acids (SCFA) can increase GI inflammation since SCFA
induce regulatory T cells (Treg) via inhibition of histone deacetylase activity. Furthermore, SCFA promote IL-18-induced epithelial repair via inflammasome
activation. The microbiota profile associated with metabolic syndrome comprises an increase in Firmicutes and a reduction in Bacteroides. The obese
microbiome has an increased capacity to harvest energy from the diet, leading to increased hepatic lipogenesis and storage of triglycerides (TG) in
adipocytes. Furthermore, the browning of fat is regulated by the microbiota. Inflammation-associated alterations in the gut microbial composition leads to
epithelial barrier disruption allowing bacterial lipopolysaccharide to circulate systemically. These metabolic changes can lead to glucose intolerance and
obesity. Allergic inflammation is associated with the lower abundance of specific bacterial genera. Depleting the gut microbiota has been shown to increase
IgE production, which together with reduced Treg responses can result in allergic inflammation. A lack of microbial competition in the gut lumen can lead to
Clostridium difficile colonisation. Finally, a lack of microbial signals can also reduce the innate as well as adaptive immune response to microorganisms,
making the host more vulnerable to infections. See the text for further details.
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responses to infection. Absence of microbiota derived signals
conferred susceptibility to systemic Listeria monocytogenes and Staphy-
lococcus aureus infection, which was driven by defects in
tissue-resident myeloid populations prior to infection.90
Microbiota signalling can also calibrate the activation threshold of
innate immune cells, that enhances the sensitivity to detect pathogen
invasion. On infection with mouse cytomegalovirus and lymphocytic
choriomeningitis virus, antiviral defences including type I interferon
(IFN) are stimulated through PRR ligation.91 In GF mice, type I IFN
dependent priming of natural killer cells was reduced due to
dampened PRR signalling, and antiviral protection was lost.91
Microbiota signalling has also been shown to enhance protection
against influenza virus by facilitating inflammasome dependent IL-1β
and IL-18 in the lung in a TLR dependent manner.20 Reactive oxygen
species-mediated defence of alveolar macrophages in respiratory
Klebsiella pneumonia infection was modulated by the gut microbiota as
well.92 Interestingly, only gut and not lung microbiota derived ligands
activated this respiratory defence mechanism, demonstrating the
importance of the gut microbiota in establishing immune defences
at other microbiota colonised sites.92
The capacity to mount adaptive immune responses is influenced by
gut microbial signals as well. This was clearly demonstrated in a mouse
model of seasonal trivalent influenza vaccination (TIV), where the
absence of gut microbiota significantly attenuated the magnitude of
vaccine-induced protective antibody response.93 A mechanistic role
was elucidated, demonstrating TLR5 mediated sensing of the gut
microbiota increased the magnitude of the antibody response.93
Furthermore, these investigations found a correlation between TLR5
expression in peripheral blood mononuclear cells shortly after
vaccination and the magnitude of TIV-induced antibody response in
a clinical cohort. The authors suggest the observed variable efficacy of
TIV between vaccines may in part be attributed to the host’s gut
microbiota composition.93 This raises the possibility that beneficial
modulation of the gut microbiota may be used as a therapeutic
approach to improve the efficacy of vaccine-induced immunity.
Manipulating gut microbes to enhance immune function is not a
new concept to be tested in the clinic. At present the studies
examining prebiotic intervention have failed to demonstrate efficacy
to increase vaccine responsiveness.94 Variability observed in the
effectiveness of probiotic interventions in vaccination trials needs to be
acknowledged.95 However, there is strong evidence across these
clinical trials to demonstrate that probiotic supplementation in adults
improves vaccine-induced immunity. For example, Bifidobacterium
lactis Bl-04 and Lactobacillus acidophilus La-14 significantly enhanced
cholera toxin-specific IgG induced by oral cholera vaccine,95
and Lactobaccillus paracasei subsp. paracacei (L. casei 431) strain
significantly increased influenza-specific IgG in response to parenteral
TIV vaccination.96 Moreover, L. casei 431 along with a number of
other candidate strains, have also demonstrated a protective effect
against acute upper respiratory tract infections.86
These studies provide clear evidence of a role for the gut microbiota
in immunity to infection as well as vaccine-induced protective
antibody responses.
DISCUSSION AND FUTURE DIRECTIONS
As most gut microbes (especially anaerobes) cannot be cultured easily,
the development of new culture-independent techniques have led to
an increase in knowledge in the gut microbiota field. These modern
technological applications are now used frequently in both pre- and
clinical studies to address the role of the gut microbiota in health and
disease (Figure 2), and have substantially contributed to providing
understanding of the complex interplay between gut microbial
composition, host genetics and biological outcomes.
Studies in GF mice, which like newborns can be colonised by a
diverse microbiota, demonstrate that a specific microbial composition
can exert lasting effects on the immunity and disease outcomes of the
host. It is only recently that investigators have begun to truly
appreciate the importance of this, and translation of such findings
into humans is challenging. So far there are only correlations between
alterations in gut microbial composition and inflammatory and
infectious diseases in humans. The humanised mouse models, when
combined with current technologies, are a promising attempt to move
beyond these correlations to provide causal roles for specific gut
microbial functions and disease susceptibility. Colonisation with the
culture collections from a human donor can be used to determine
which cultured members of the microbiota can transmit or prevent a
disease phenotype, and these studies may identify viable microbial-
based therapeutic targets. It also opens up possibilities to study the
effects of dietary components on gut microbiota composition and
disease outcome, or to evaluate the ability of bacterial strains with a
therapeutic potential to invade established niches in gut communities.
GF and gnotobiotic models provide a great tool to study the
microbiota, but as with all animal models there are limitations around
the translation to the clinical setting. These models might not
completely recapitulate the human disease complexity or heterogeneity
of the human gut microbiota.26 Humanised mouse studies have the
added complexity of the donor microbiota not having co-evolved with
a mouse host, and studies have shown host-specific gut microbiota
may be critical for an appropriately functioning immune system.97
Nonetheless, these model systems are invaluable for the understanding
of host–microbiota interactions that contribute to disease.
Beneficial modulation of the gut microbiota has yielded encoura-
ging results for the prevention and treatment of various inflammatory
diseases in experimental models. Further work is required to
characterise strain-specific effects and efficacious dosing regimens for
prebiotics and probiotics. Alongside, fundamental research needs to be
conducted to define the mechanisms by which the gut microbiota can
enhance immune health. Most likely non-bacterial microbes also have
an important role in immune function and disease. Their contribution
remains an important area for future research, as this has been
relatively unexplored to date. This is a fast-paced field of research and
given the positive results so far, we are cautiously optimistic it will
soon yield novel therapeutics that manipulate the microbiota to
prevent or treat chronic inflammatory diseases and enhance protective
immunity against pathogens.
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